Categories
Life Sciences Consumer Goods Materials and Chemicals Construction & Manufacturing Food and Beverages Energy and Power Semiconductor and Electronics Automotive and Transportation ICT & Media Aerospace & Defense BFSI

Int'l : +1-503-894-6022 | Toll Free : +1-800-792-5285 | help@alliedmarketresearch.com

Lyme Disease Diagnostics Market by Emerging Diagnostic Technology (Serological Test, Urine Antigen Tests, Lymphocytic Transformation Test, Immunofluorescent Staining, Nucleic acid Test) and by End User (Hospitals, Public/Private Laboratories, Physicians Office): Global Opportunity Analysis and Industry Forecast, 2023-2032

A04061

Pages: NA

Charts: NA

Tables: NA

Lyme disease is a bacterial infection caused by species borrelia. It generally spreads in the humans through infected ticks bite. Patients infected with Lyme disease suffer from symptoms such as depression, fever, fatigue, and skin rashes. If the disease is diagnosed at an early stage then it can be treated with antibiotics. However, if the disease is left untreated then it affects, joint, heart, and central nervous system, and might become a cause for death.

Rise in prevalence of Lyme disease, increase in focus of government toward improvement of healthcare facilities, and emergence of new Lyme disease diagnostic tests drive the market. However, lack of awareness regarding the disease and inefficiency in Lyme disease testing majorly restricts the market. In addition, growth in interests of key players toward R&D of Lyme disease diagnosis is expected to provide lucrative growth opportunities for the market.

The report segments the global Lyme disease diagnostics market based on emerging diagnostic technology and end user. By diagnostic technology, the market is classified into serological test (ELISA and Western Blot), urine antigen tests, lymphocytic transformation test, immunofluorescent staining, nucleic acid test, and others. Based on end user, the market is categorized into hospitals, public/private laboratories, and physicians office. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The key players of the global Lyme disease diagnostics market include Abbott Laboratories, T2 Biosystems, Canon Life Sciences, Bio-Rad Laboratories, Alere Inc., Roche Diagnostics International Ltd., Graphene Frontiers, Covance Inc., Immunetics Inc., GlaxoSmithKline Pharmaceuticals Ltd., Boulder Diagnostics, Affymetrix Inc., Siemens AG, Baxter International Inc., and Fresenius Medical Care AG & Co.

Key Benefits

  • The study provides an in-depth analysis of the global Lyme disease diagnostics market and the current trends and future estimations to elucidate the imminent investment pockets.
  • The report presents quantitative analysis of the market to enable stakeholders to capitalize on the prevailing market opportunities.
  • Extensive analysis of the market based on product assists to understand the trends in the industry.
  • Key market players and their strategies are thoroughly analyzed to understand the competitive outlook of the industry.

 Key Market Segments

  • By Emerging Diagnostic Technology
    • Serological Test
      • ELISA
      • Western Blot
    • Urine Antigen Tests
    • Lymphocytic Transformation Test
    • Immunofluorescent Staining
    • Nucleic acid Test
  • By End User
    • Hospitals
    • Public/Private Laboratories
    • Physicians Office
  • By Region
    • North America
      • U.S.
      • Canada
      • Mexico
    • Europe
      • France
      • Germany
      • Italy
      • Spain
      • UK
      • Rest of Europe
    • Asia-Pacific
      • China
      • Japan
      • India
      • South Korea
      • Australia
      • Rest of Asia-Pacific
    • LAMEA
      • Brazil
      • South Africa
      • Saudi Arabia
      • Rest of LAMEA

 
Key Market Players

  • GlaxoSmithKline
  • Immunetics Inc.
  • Roche Diagnostics International Ltd.
  • Bio Rad Laboratories
  • T2 Biosystems
  • Covance Inc.
  • Alere Inc.
  • Graphene Frontiers
  • Canon Life Sciences
  • Abbott Laboratories

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

  • CHAPTER 4: LYME DISEASE DIAGNOSTICS MARKET, BY EMERGING DIAGNOSTIC TECHNOLOGY

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Emerging Diagnostic Technology

    • 4.2. Serological Test

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

      • 4.2.4. ELISA

        • 4.2.4.1. Market Size and Forecast

      • 4.2.4. Western Blot

        • 4.2.4.1. Market Size and Forecast

    • 4.3. Urine Antigen Tests

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

    • 4.4. Lymphocytic Transformation Test

      • 4.4.1. Key Market Trends, Growth Factors and Opportunities

      • 4.4.2. Market Size and Forecast, By Region

      • 4.4.3. Market Share Analysis, By Country

    • 4.5. Immunofluorescent Staining

      • 4.5.1. Key Market Trends, Growth Factors and Opportunities

      • 4.5.2. Market Size and Forecast, By Region

      • 4.5.3. Market Share Analysis, By Country

    • 4.6. Nucleic Acid Test

      • 4.6.1. Key Market Trends, Growth Factors and Opportunities

      • 4.6.2. Market Size and Forecast, By Region

      • 4.6.3. Market Share Analysis, By Country

  • CHAPTER 5: LYME DISEASE DIAGNOSTICS MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Public/Private Laboratories

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Physicians Office

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: LYME DISEASE DIAGNOSTICS MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Emerging Diagnostic Technology

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Lyme Disease Diagnostics Market

        • 6.2.5.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Lyme Disease Diagnostics Market

        • 6.2.6.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Lyme Disease Diagnostics Market

        • 6.2.7.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Emerging Diagnostic Technology

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Lyme Disease Diagnostics Market

        • 6.3.5.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Lyme Disease Diagnostics Market

        • 6.3.6.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Lyme Disease Diagnostics Market

        • 6.3.7.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Lyme Disease Diagnostics Market

        • 6.3.8.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Lyme Disease Diagnostics Market

        • 6.3.9.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Lyme Disease Diagnostics Market

        • 6.3.10.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Lyme Disease Diagnostics Market

        • 6.3.11.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Emerging Diagnostic Technology

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Lyme Disease Diagnostics Market

        • 6.4.5.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Lyme Disease Diagnostics Market

        • 6.4.6.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Lyme Disease Diagnostics Market

        • 6.4.7.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Lyme Disease Diagnostics Market

        • 6.4.8.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Lyme Disease Diagnostics Market

        • 6.4.9.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Lyme Disease Diagnostics Market

        • 6.4.10.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Lyme Disease Diagnostics Market

        • 6.4.11.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Lyme Disease Diagnostics Market

        • 6.4.12.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Lyme Disease Diagnostics Market

        • 6.4.13.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Emerging Diagnostic Technology

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Lyme Disease Diagnostics Market

        • 6.5.5.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Lyme Disease Diagnostics Market

        • 6.5.6.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Lyme Disease Diagnostics Market

        • 6.5.7.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Lyme Disease Diagnostics Market

        • 6.5.8.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Lyme Disease Diagnostics Market

        • 6.5.9.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Lyme Disease Diagnostics Market

        • 6.5.10.1. Market Size and Forecast, By Emerging Diagnostic Technology
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning, 2024

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. Abbott Laboratories

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. T2 Biosystems

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Canon Life Sciences

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Bio Rad Laboratories

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. Alere Inc.

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Roche Diagnostics International Ltd.

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. Graphene Frontiers

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. Covance Inc.

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Immunetics Inc.

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. GlaxoSmithKline

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL LYME DISEASE DIAGNOSTICS MARKET, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 2. GLOBAL LYME DISEASE DIAGNOSTICS MARKET FOR SEROLOGICAL TEST, BY REGION, 2025-2033 ($MILLION)
  • TABLE 3. GLOBAL LYME DISEASE DIAGNOSTICS MARKET FOR URINE ANTIGEN TESTS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 4. GLOBAL LYME DISEASE DIAGNOSTICS MARKET FOR LYMPHOCYTIC TRANSFORMATION TEST, BY REGION, 2025-2033 ($MILLION)
  • TABLE 5. GLOBAL LYME DISEASE DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENT STAINING, BY REGION, 2025-2033 ($MILLION)
  • TABLE 6. GLOBAL LYME DISEASE DIAGNOSTICS MARKET FOR NUCLEIC ACID TEST, BY REGION, 2025-2033 ($MILLION)
  • TABLE 7. GLOBAL LYME DISEASE DIAGNOSTICS MARKET, BY END USER, 2025-2033 ($MILLION)
  • TABLE 8. GLOBAL LYME DISEASE DIAGNOSTICS MARKET FOR HOSPITALS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 9. GLOBAL LYME DISEASE DIAGNOSTICS MARKET FOR PUBLIC/PRIVATE LABORATORIES, BY REGION, 2025-2033 ($MILLION)
  • TABLE 10. GLOBAL LYME DISEASE DIAGNOSTICS MARKET FOR PHYSICIANS OFFICE, BY REGION, 2025-2033 ($MILLION)
  • TABLE 11. GLOBAL LYME DISEASE DIAGNOSTICS MARKET, BY REGION, 2025-2033 ($MILLION)
  • TABLE 12. NORTH AMERICA LYME DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 13. NORTH AMERICA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 14. NORTH AMERICA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 15. U.S. LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 16. U.S. LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 17. CANADA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 18. CANADA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 19. MEXICO LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 20. MEXICO LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 21. EUROPE LYME DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 22. EUROPE LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 23. EUROPE LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 24. FRANCE LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 25. FRANCE LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 26. GERMANY LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 27. GERMANY LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 28. ITALY LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 29. ITALY LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 30. SPAIN LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 31. SPAIN LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 32. UK LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 33. UK LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 34. RUSSIA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 35. RUSSIA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 36. REST OF EUROPE LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 37. REST OF EUROPE LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 38. ASIA-PACIFIC LYME DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 39. ASIA-PACIFIC LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 40. ASIA-PACIFIC LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 41. CHINA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 42. CHINA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 43. JAPAN LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 44. JAPAN LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 45. INDIA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 46. INDIA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 47. SOUTH KOREA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 48. SOUTH KOREA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 49. AUSTRALIA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 50. AUSTRALIA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 51. THAILAND LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 52. THAILAND LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 53. MALAYSIA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 54. MALAYSIA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 55. INDONESIA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 56. INDONESIA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 57. REST OF ASIA PACIFIC LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 58. REST OF ASIA PACIFIC LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 59. LAMEA LYME DISEASE DIAGNOSTICS, BY REGION, 2025-2033 ($MILLION)
  • TABLE 60. LAMEA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 61. LAMEA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 62. BRAZIL LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 63. BRAZIL LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 64. SOUTH AFRICA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 65. SOUTH AFRICA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 66. SAUDI ARABIA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 67. SAUDI ARABIA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 68. UAE LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 69. UAE LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 70. ARGENTINA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 71. ARGENTINA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 72. REST OF LAMEA LYME DISEASE DIAGNOSTICS, BY EMERGING DIAGNOSTIC TECHNOLOGY, 2025-2033 ($MILLION)
  • TABLE 73. REST OF LAMEA LYME DISEASE DIAGNOSTICS, BY END USER, 2025-2033 ($MILLION)
  • TABLE 74. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 75. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 76. ABBOTT LABORATORIES: OPERATING SEGMENTS
  • TABLE 77. ABBOTT LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 78. ABBOTT LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 79. T2 BIOSYSTEMS: KEY EXECUTIVES
  • TABLE 80. T2 BIOSYSTEMS: COMPANY SNAPSHOT
  • TABLE 81. T2 BIOSYSTEMS: OPERATING SEGMENTS
  • TABLE 82. T2 BIOSYSTEMS: PRODUCT PORTFOLIO
  • TABLE 83. T2 BIOSYSTEMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 84. CANON LIFE SCIENCES: KEY EXECUTIVES
  • TABLE 85. CANON LIFE SCIENCES: COMPANY SNAPSHOT
  • TABLE 86. CANON LIFE SCIENCES: OPERATING SEGMENTS
  • TABLE 87. CANON LIFE SCIENCES: PRODUCT PORTFOLIO
  • TABLE 88. CANON LIFE SCIENCES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 89. BIO RAD LABORATORIES: KEY EXECUTIVES
  • TABLE 90. BIO RAD LABORATORIES: COMPANY SNAPSHOT
  • TABLE 91. BIO RAD LABORATORIES: OPERATING SEGMENTS
  • TABLE 92. BIO RAD LABORATORIES: PRODUCT PORTFOLIO
  • TABLE 93. BIO RAD LABORATORIES: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 94. ALERE INC.: KEY EXECUTIVES
  • TABLE 95. ALERE INC.: COMPANY SNAPSHOT
  • TABLE 96. ALERE INC.: OPERATING SEGMENTS
  • TABLE 97. ALERE INC.: PRODUCT PORTFOLIO
  • TABLE 98. ALERE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 99. ROCHE DIAGNOSTICS INTERNATIONAL LTD.: KEY EXECUTIVES
  • TABLE 100. ROCHE DIAGNOSTICS INTERNATIONAL LTD.: COMPANY SNAPSHOT
  • TABLE 101. ROCHE DIAGNOSTICS INTERNATIONAL LTD.: OPERATING SEGMENTS
  • TABLE 102. ROCHE DIAGNOSTICS INTERNATIONAL LTD.: PRODUCT PORTFOLIO
  • TABLE 103. ROCHE DIAGNOSTICS INTERNATIONAL LTD.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 104. GRAPHENE FRONTIERS: KEY EXECUTIVES
  • TABLE 105. GRAPHENE FRONTIERS: COMPANY SNAPSHOT
  • TABLE 106. GRAPHENE FRONTIERS: OPERATING SEGMENTS
  • TABLE 107. GRAPHENE FRONTIERS: PRODUCT PORTFOLIO
  • TABLE 108. GRAPHENE FRONTIERS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 109. COVANCE INC.: KEY EXECUTIVES
  • TABLE 110. COVANCE INC.: COMPANY SNAPSHOT
  • TABLE 111. COVANCE INC.: OPERATING SEGMENTS
  • TABLE 112. COVANCE INC.: PRODUCT PORTFOLIO
  • TABLE 113. COVANCE INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 114. IMMUNETICS INC.: KEY EXECUTIVES
  • TABLE 115. IMMUNETICS INC.: COMPANY SNAPSHOT
  • TABLE 116. IMMUNETICS INC.: OPERATING SEGMENTS
  • TABLE 117. IMMUNETICS INC.: PRODUCT PORTFOLIO
  • TABLE 118. IMMUNETICS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 119. GLAXOSMITHKLINE: KEY EXECUTIVES
  • TABLE 120. GLAXOSMITHKLINE: COMPANY SNAPSHOT
  • TABLE 121. GLAXOSMITHKLINE: OPERATING SEGMENTS
  • TABLE 122. GLAXOSMITHKLINE: PRODUCT PORTFOLIO
  • TABLE 123. GLAXOSMITHKLINE: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL LYME DISEASE DIAGNOSTICS MARKET SEGMENTATION
  • FIGURE 2. GLOBAL LYME DISEASE DIAGNOSTICS MARKET
  • FIGURE 3. SEGMENTATION LYME DISEASE DIAGNOSTICS MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN LYME DISEASE DIAGNOSTICS MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALLYME DISEASE DIAGNOSTICS MARKET
  • FIGURE 11. LYME DISEASE DIAGNOSTICS MARKET SEGMENTATION, BY BY EMERGING DIAGNOSTIC TECHNOLOGY
  • FIGURE 12. LYME DISEASE DIAGNOSTICS MARKET FOR SEROLOGICAL TEST, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 13. LYME DISEASE DIAGNOSTICS MARKET FOR URINE ANTIGEN TESTS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 14. LYME DISEASE DIAGNOSTICS MARKET FOR LYMPHOCYTIC TRANSFORMATION TEST, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 15. LYME DISEASE DIAGNOSTICS MARKET FOR IMMUNOFLUORESCENT STAINING, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 16. LYME DISEASE DIAGNOSTICS MARKET FOR NUCLEIC ACID TEST, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 17. LYME DISEASE DIAGNOSTICS MARKET SEGMENTATION, BY BY END USER
  • FIGURE 18. LYME DISEASE DIAGNOSTICS MARKET FOR HOSPITALS, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 19. LYME DISEASE DIAGNOSTICS MARKET FOR PUBLIC/PRIVATE LABORATORIES, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 20. LYME DISEASE DIAGNOSTICS MARKET FOR PHYSICIANS OFFICE, BY COUNTRY, 2025-2033 ($MILLION)
  • FIGURE 21. TOP WINNING STRATEGIES, BY YEAR, 2022-2024*
  • FIGURE 22. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2022-2024*
  • FIGURE 23. TOP WINNING STRATEGIES, BY COMPANY, 2022-2024*
  • FIGURE 24. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 25. COMPETITIVE DASHBOARD
  • FIGURE 26. COMPETITIVE HEATMAP: LYME DISEASE DIAGNOSTICS MARKET
  • FIGURE 27. TOP PLAYER POSITIONING, 2024
  • FIGURE 28. ABBOTT LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 29. ABBOTT LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 30. ABBOTT LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 31. T2 BIOSYSTEMS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 32. T2 BIOSYSTEMS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 33. T2 BIOSYSTEMS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 34. CANON LIFE SCIENCES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 35. CANON LIFE SCIENCES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 36. CANON LIFE SCIENCES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 37. BIO RAD LABORATORIES: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 38. BIO RAD LABORATORIES: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 39. BIO RAD LABORATORIES: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 40. ALERE INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 41. ALERE INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 42. ALERE INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 43. ROCHE DIAGNOSTICS INTERNATIONAL LTD.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 44. ROCHE DIAGNOSTICS INTERNATIONAL LTD.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 45. ROCHE DIAGNOSTICS INTERNATIONAL LTD.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 46. GRAPHENE FRONTIERS: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 47. GRAPHENE FRONTIERS: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 48. GRAPHENE FRONTIERS: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 49. COVANCE INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 50. COVANCE INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 51. COVANCE INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 52. IMMUNETICS INC.: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 53. IMMUNETICS INC.: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 54. IMMUNETICS INC.: REVENUE SHARE, BY REGION, 2024 (%)
  • FIGURE 55. GLAXOSMITHKLINE: NET SALES, 2022-2024 ($MILLION)
  • FIGURE 56. GLAXOSMITHKLINE: REVENUE SHARE, BY SEGMENT, 2024 (%)
  • FIGURE 57. GLAXOSMITHKLINE: REVENUE SHARE, BY REGION, 2024 (%)

Purchase Full Report of
Lyme Disease Diagnostics Market

PURCHASE OPTIONS



* Taxes/Fees, If applicable will be added during checkout. All prices in USD.

Have a question ?

Need to add more ?

Avail up to 30% discount on subscription plans on


Avenue

© 2025 Allied Market Research. All Rights Reserved